Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 12:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–6 of 6 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, Prostate Cancer, Breast Cancer, Ovarian Cancer, Loss of Appetite, Fatigue, Cachexia, Anorexia
Interventions
PF-06946860, Placebo for PF-06946860
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
32
States / cities
Little Rock, Arkansas • Beverly Hills, California • Camarillo, California + 21 more
Conditions
Healthy
Interventions
PF-06946860, Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Conditions
Healthy
Interventions
PF-06946860, Placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Anaheim, California
Conditions
Cachexia, Non-Small-Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer
Interventions
PF-06946860
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
10
States / cities
Beverly Hills, California • Grand Junction, Colorado • Wheat Ridge, Colorado + 7 more
Terminated Phase 2 Interventional Results available

A Study of Ponsegromab in People With Heart Failure

NCT05492500
Conditions
Heart Failure
Interventions
Main cohort (Cohort A): Ponsegromab low dose, Main cohort (Cohort A): Ponsegromab medium dose, Main cohort (Cohort A): ponsegromab high dose, Main cohort (Cohort A): Matched placebo, Open-label, PK Cohort (Cohort B): ponsegromab low dose, Open-label, PK Cohort (Cohort B): ponsegromab medium dose, Open-label, PK Cohort (Cohort B): ponsegromab high dose, Optional Cohort C: Ponsegromab low dose, Optional Cohort C: Matched placebo, Optional Cohort D: Ponsegromab high dose, Optional Cohort D: Matched placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
22
States / cities
Fairhope, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 13 more
Conditions
Cachexia, Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
ponsegromab, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
982 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
83
States / cities
Birmingham, Alabama • Phoenix, Arizona • Bryant, Arkansas + 45 more